US Biobanking Market Research Report By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Application (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations) and By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage) - Forecast to 2035

US Biobanking Market Overview

As per MRFR analysis, the US Biobanking Market Size was estimated at 1.38 (USD Billion) in 2023. The US Biobanking Market Industry is expected to grow from 1.45 (USD Billion) in 2024 to 2.32 (USD Billion) by 2035. The US Biobanking Market CAGR (growth rate) is expected to be around 4.365% during the forecast period (2025 - 2035).

Key US Biobanking Market Trends Highlighted

The US biobanking market is experiencing significant trends driven by advances in genomic research and personalized medicine. The increasing demand for biobanks is largely fueled by the rising prevalence of chronic diseases, which necessitate a deeper understanding of genetic and environmental factors. Additionally, initiatives from government bodies such as the National Institutes of Health support biobanking efforts, pushing for the establishment of comprehensive databases to facilitate cutting-edge research.

This has created opportunities for collaboration among academic institutions, pharmaceuticals, and biotechnology firms to leverage biobanks for drug discovery and development. Opportunities to be explored include the integration of artificial intelligence and machine learning in managing biobanking data, enhancing the ability to analyze vast amounts of biological samples efficiently. There is also a growing trend towards biobanks being recognized not just as storage facilities but as active participants in research networks, promoting transparency and access to diverse populations.

This is important as it ensures that minority groups are also represented in genetic studies, addressing past biases in research. Trends in recent times have also shown an increased focus on ethical considerations in biobanking, emphasizing informed consent and participant privacy. Regulations from the US Department of Health & Human Services reinforce the importance of ethical practices in biobanking, ensuring the protection of individual rights while fostering public trust. Overall, these trends reflect a dynamic US biobanking market that is keen on innovation, collaboration, and ethical responsibility, aiming to advance healthcare outcomes through effective use of biological materials.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Biobanking Market Drivers

Increasing Investments in Research and Development

The US Biobanking Market Industry is experiencing significant growth driven by escalating investments in Research and Development initiatives. According to the National Institutes of Health (NIH), the US government allocated approximately 41 billion USD for biomedical research in recent years, fostering advancements that directly impact biobanking practices. This monetary commitment enables the development of innovative technologies for specimen collection, processing, and storage, leading to improved biobanking efficiencies.

Moreover, such increased funding is likely to enhance collaborations between academic institutions and biobanks, resulting in the establishment of unique biorepositories that cater to specific diseases. Companies like Thermo Fisher Scientific, specializing in biobanking equipment and services, are leveraging these advancements to create comprehensive solutions for researchers. The alignment of governmental funding with private sector innovations presents a robust foundation for the growth of the US Biobanking Market Industry, signifying its potential to reach new heights in the coming years.

Rising Incidence of Chronic Diseases

The US Biobanking Market Industry is significantly influenced by the growing incidence of chronic diseases, including cancer, diabetes, and cardiovascular conditions. According to the Centers for Disease Control and Prevention (CDC), around 6 in 10 adults in the US have a chronic disease, and 4 in 10 adults have two or more chronic conditions. This alarming trend drives the need for extensive biobank collections, as researchers require diverse biological samples to study disease etiology and treatment.

Established biobanks, such as the Biorepository of the National Cancer Institute, play a pivotal role in providing access to critical biological specimens for research purposes. By facilitating large-scale genetic studies and clinical trials, biobanks help advance personalized medicine, thereby enhancing the demand for their services. This increased focus on chronic disease research will significantly bolster the US Biobanking Market Industry.

Technological Advancements in Biobanking Processes

The advancement of technology in biobanking, specifically in storage and data management systems, is a driving force behind the growth of the US Biobanking Market Industry. Innovations such as automated sample management systems and advanced cryopreservation techniques have improved specimen quality and integrity. A report from the Food and Drug Administration (FDA) highlights that effective data management and tracking of biological samples can enhance research outcomes and ensure regulatory compliance.

Companies like Qiagen are innovating to provide solutions that streamline sample processing and enhance the performance of biobanks. Technological improvements not only facilitate better management of biobanks but also promote collaboration between various research entities, making the US Biobanking Market Industry a crucial component of modern biomedical research.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is accelerating the growth of the US Biobanking Market Industry. The Food and Drug Administration (FDA) states that personalized medicine uses individual genetic profiles to tailor treatments, which necessitates access to a variety of biological specimens from diverse populations. According to the Personalized Medicine Coalition, around 29 million US patients have received treatments adjusted for their genetic makeup.

Biobanks are essential in providing the samples needed for these targeted therapies, enabling better health outcomes. Companies such as IBM and Genentech are actively involved in integrating biobanking data with genomic information to foster advancements in precision medicine. This synergy of biobank samples with personalized treatments is likely to drive demand and solidify the US Biobanking Market Industry's role in future healthcare innovation.

US Biobanking Market Segment Insights

Biobanking Market Sample Type Insights

The Sample Type segment of the US Biobanking Market comprises various categories that are crucial for advancing medical research and patient care. This segment includes Blood Products, Tissues, Cells, Nucleic Acids, and Microbiome Samples, each offering distinct advantages for different areas in Research and Development. Blood Products represent a substantial portion of biobanking efforts as they are vital for clinical applications and research on hematological disorders and transfusions. Tissues obtained from various sources are equally important, facilitating the understanding of disease mechanisms and the development of targeted therapies.

Moreover, Cells, including both primary cells and cell lines, play a significant role in regenerative medicine and drug testing, highlighting their relevance in therapeutic innovations. Nucleic Acids, which encompass DNA and RNA samples, are critical for genetic studies, biomarker discovery, and personalized medicine, reflecting the growing trend towards precision health. Additionally, Microbiome Samples have gained attention due to their implications in understanding human health and diseases, particularly in areas like gut health and immunology. Each of these sample types contributes to enhancing the US Biobanking Market's data richness, supporting ongoing studies aimed at improving healthcare outcomes.

Overall, the focus on these diverse sample types exemplifies the broader trends in biobanking, which emphasize the importance of collaboration among researchers, clinicians, and biobank facilities to drive innovation in this essential industry. As biobanks continue to expand their capabilities and collections, they not only contribute to scientific advancements but also address the growing demand for materials that can support a spectrum of research initiatives across the United States.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Biobanking Market Application Insights

The Application segment of the US Biobanking Market plays a critical role in driving innovation within the healthcare industry. Focused on areas such as Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine, this segment is essential for advancing medical research and improving patient outcomes. Research and Development ensures that new therapeutics are effectively discovered and tested, while Clinical Trials provide the necessary framework for assessing these innovations in real-world settings. Personalized Medicine tailors treatment approaches to individual genetic profiles, offering significant advantages in efficacy and safety compared to traditional methods.

Regenerative Medicine aims to replace or repair damaged cells and tissues, marking a significant shift in treating chronic diseases and injuries. These applications collectively contribute to the market's growth, fueled by increasing investments in biotechnology and supportive government initiatives aimed at enhancing health outcomes in the United States. In this context, the US Biobanking Market segmentation reflects a diverse array of opportunities driven by scientific advancements and the rising need for personalized health solutions in a rapidly evolving healthcare landscape.

Biobanking Market End Use Insights

The US Biobanking Market has demonstrated significant growth potential, particularly within the End Use segment, which encompasses various crucial entities such as Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a pivotal role in advancing biomedical research by providing essential biological samples, which support numerous studies and enhance the understanding of complex diseases. Biotechnology Companies often rely on biobanks for critical testing and development of novel therapeutics, fostering innovation in the industry.

Pharmaceutical Companies leverage biobanks to facilitate drug development processes, ensuring efficient translation of research findings into actionable treatments. Government Organizations contribute by supporting biobanking initiatives that aim to advance public health initiatives, disease prevention, and environmental studies. The collective efforts of these entities underscore the importance of biobanking in driving medical research, improving patient outcomes, and forming a foundation for the development of new healthcare solutions. As the focus on personalized medicine and genetic research continues to grow, these sectors are expected to play increasingly vital roles in shaping the US Biobanking Market landscape.

Furthermore, challenges and opportunities concerning data management, ethical considerations, and regulatory frameworks remain intrinsic to the evolution of biobanking practices in the United States.

Biobanking Market Storage Type Insights

The Storage Type segment of the US Biobanking Market is critical for enabling effective long-term preservation of biological samples, which is fundamental for research and clinical applications. Vapor Phase Storage is increasingly favored due to its efficient nitrogen usage and lower risk of contamination, making it suitable for sensitive cell lines and biological specimens. Liquid Phase Storage, while traditionally employed, is witnessing a transformation with advancements in technology that enhance its reliability for sample integrity. Cryopreservation Storage plays a significant role in the market as it facilitates the preservation of cells, tissues, and organs at extremely low temperatures, enabling successful long-term storage.

This technique is essential for maintaining the viability of samples for extended periods, ensuring that biobanks can support various applications, including Research and Development activities. As the US faces a growing demand for personalized medicine and advanced therapies, the importance of effective storage solutions cannot be understated, making this segment a key driver of US Biobanking Market growth. Overall, the diversity of storage methods and their evolving technologies highlight the market's adaptability to changing scientific needs and the pursuit of innovation.

US Biobanking Market Key Players and Competitive Insights

The US Biobanking Market is an essential component of the healthcare and research landscape, driven by advancements in biotechnologies and genetic research. The competitive insights within this sector reveal a dynamic environment where various players are constantly innovating to meet the growing demand for biobanks and biorepositories. Factors such as technological advancements, regulatory frameworks, and collaborations between academic, public, and private sectors significantly impact competition. The crucial role of biobanks in personalized medicine, drug discovery, and disease research creates a lucrative market for stakeholders, each aiming to capture a share through unique offerings, efficient operations, and strategic partnerships.

With a profound emphasis on quality, compliance, and data management, companies in the biobanking space must continuously adapt to the evolving needs of researchers and pharmaceutical companies.

Molecular X

Molecular X has established itself as a formidable player in the US Biobanking Market, focusing on the collection, storage, and distribution of biological samples. The company is recognized for its robust operational capabilities and has developed advanced techniques that ensure sample integrity while maintaining high ethical standards. Molecular X's strong presence in the US can be attributed to its commitment to quality control and innovative storage solutions, which lend credibility to the biobanks it operates. Additionally, its strategic collaborations with leading research institutions and healthcare organizations enhance its market standing, fostering trust and reliability. The company's emphasis on cutting-edge technology not only streamlines the biobanking process but also expands its range of services, positioning it well against competitors in this evolving landscape.

Global BioResource

Global BioResource is another key player within the US Biobanking Market, offering a comprehensive range of products and services designed to support research and clinical applications. The company's portfolio includes biologic sample collection, biorepository management software, and analytical services that cater to a diverse clientele. Global BioResource's market presence has been strengthened by its strategic mergers and acquisitions, which have expanded its operational capabilities and geographic reach within the US. The company's strengths lie in its innovative approaches to sample processing, efficient logistics, and data management, making it an attractive partner for research institutions and pharmaceutical companies alike. With a strong focus on compliance and quality assurance, Global BioResource has positioned itself as a trusted resource in the biobanking sector, enabling researchers to access high-quality biological materials essential for advancing scientific discoveries.

Key Companies in the US Biobanking Market Include

• Molecular X


• Global BioResource


• Bioclinica


• Cypress Biotech


• Brooks Life Sciences


• Trevigen


• PerkinElmer


• Thermo Fisher Scientific


• Kamina Biotherapeutics


• U.S. Biolab


• Asterand Bioscience


• BioStorage Technologies


• Qiagen


• SeraCare Life Sciences


• BD

US Biobanking Market Industry Developments

The US Biobanking Market has witnessed significant advancements and changes recently. Companies like Molecular X and Global BioResource are focusing on expanding their biobanking capabilities to cater to the rising demand for personalized medicine and genomic research. In recent developments, PerkinElmer has launched innovative solutions aimed at enhancing sample analysis and storage efficiency, while Thermo Fisher Scientific continues to enhance its infrastructure to support biobanks across the nation. 

A notable merger occurred in August 2023, when BD acquired a biotechnology firm that specializes in biobank solutions, strengthening its position in the market. Additionally, companies such as SeraCare Life Sciences and Brooks Life Sciences are driving growth through technological innovations in sample management and storage systems. The market valuation is also experiencing an uptick due to increased investment in biobanking initiatives, reflecting a strong demand for high-quality biospecimens in clinical trials and research. Overall, the US Biobanking Market continues to evolve with robust participation from key players while maintaining a focus on advancing healthcare outcomes through meticulous biobanking processes.

US Biobanking Market Segmentation Insights

Biobanking Market Sample Type Outlook

• Blood Products


• Tissues


• Cells


• Nucleic Acids


• Microbiome Samples

Biobanking Market Application Outlook

• Research and Development


• Clinical Trials


• Personalized Medicine


• Regenerative Medicine

Biobanking Market End Use Outlook

• Academic Research Institutions


• Biotechnology Companies


• Pharmaceutical Companies


• Government Organizations

Biobanking Market Storage Type Outlook

• Vapor Phase Storage


• Liquid Phase Storage


• Cryopreservation Storage

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	1.38(USD Billion)
MARKET SIZE 2024	1.45(USD Billion)
MARKET SIZE 2035	2.32(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.365% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	Molecular X, Global BioResource, Bioclinica, Cypress Biotech, Brooks Life Sciences, Trevigen, PerkinElmer, Thermo Fisher Scientific, Kamina Biotherapeutics, U.S. Biolab, Asterand Bioscience, BioStorage Technologies, Qiagen, SeraCare Life Sciences, BD
SEGMENTS COVERED	Sample Type, Application, End Use, Storage Type
KEY MARKET OPPORTUNITIES	Increased genomic research funding, Personalized medicine advancements, Growing biopharmaceutical collaborations, Rising demand for rare disease studies, Expansion of digital biobanking platforms.
KEY MARKET DYNAMICS	Increasing demand for personalized medicine, Growth in genomic research initiatives, Advancements in biobanking technologies, Rising public awareness of biobanking, Regulatory framework supporting biobanking practices
COUNTRIES COVERED	US